Peter W. Gout

Peter W. Gout

Auto-generated profile, based on publicly available information

Peter W. Gout

Department of Experimental Therapeutics, BC Cancer Agency, Vancouver, BC, Canada

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2008 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MLMaisie Lo
Maisie Lo
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
PGPeter W. Gout
Peter W. Gout

31 May 2013 in The Journal of Pathology
Verified
Journal Article
Open access
PDF file
SCStephen Yiu Chuen Choi
Stephen Yiu Chuen Choi
CCColin C Collins
Colin C Collins
PGPeter W Gout
Peter W Gout
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
The common preference of cancers for lactic acid‐generating metabolic energy pathways has led to proposals that their reprogrammed metabolism confers growth advantages such as decreased susceptibility to hypoxic stress. Recent observations, however, suggest that it generates a novel way for cancer survival. There is increasing evidence that cancers can escape immune destruction by suppressing the anti‐cancer immune response through maintaining a relatively low pH in their micro‐environment. Tumours achieve this by regulating lactic acid secretion via modification of glucose/glutamine metabolisms. We propose that the maintenance by cancers of a relatively low pH in their micro‐environment, via regulation of their lactic acid secretion through selective modification of their energy metabolism, is another major mechanism by which cancers can suppress the anti‐cancer immune response. Cancer‐generated lactic acid could thus be viewed as a critical, immunosuppressive metabolite in the tumour micro-environment rather than a ‘waste product’. This paradigm shift can have major impact on therapeutic strategy development. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

22 July 2008 in British Journal of Cancer
Verified
Journal Article
Open access
MLM Lo
M Lo
VLV Ling
V Ling
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
PGP W Gout
P W Gout
The xc− cystine transporter enhances biosynthesis of glutathione, a tripeptide thiol important in drug resistance and cellular defense against oxidative stress, by enabling cellular uptake of cystine, a rate-limiting precursor. Because it is known to regulate glutathione levels and growth of various cancer cell types, and is expressed in the pancreas, we postulate that it is involved in growth and drug resistance of pancreatic cancer. To examine this, we characterised expression of the xc− transporter in pancreatic cancer cell lines, MIA PaCa-2, PANC-1 and BxPC-3, as subjected to cystine-depletion and oxidative stress. The results indicate that these cell lines depend on xc−-mediated cystine uptake for growth, as well as survival in oxidative stress conditions, and can modulate xc− expression to accommodate growth needs. Immunohistochemical analysis showed that the transporter was differentially expressed in normal pancreatic tissues and overexpressed in pancreatic cancer tissues from two patients. Furthermore, gemcitabine resistance of cells was associated with elevated xc− expression and specific xc− inhibition by monosodium glutamate led to growth arrest. The results suggest that the xc− transporter by enhancing glutathione biosynthesis plays a major role in pancreatic cancer growth, therapy resistance and represents a potential therapeutic target for the disease.

1 December 2014 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
SCStephen Yiu Chuen Choi
Stephen Yiu Chuen Choi
DLDong Lin
Dong Lin
PGPeter W. Gout
Peter W. Gout
CCColin Collins
Colin Collins
YXYong Xu
Yong Xu
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
The development of novel cancer therapeutics is often plagued by discrepancies between drug efficacies obtained in preclinical studies and outcomes of clinical trials. The inconsistencies can be attributed to a lack of clinical relevance of the cancer models used for drug testing. While commonly used in vitro culture systems are advantageous for addressing specific experimental questions, they are often gross, fidelity-lacking simplifications that largely ignore the heterogeneity of cancers as well as the complexity of the tumor microenvironment. Factors such as tumor architecture, interactions among cancer cells and between cancer and stromal cells, and an acidic tumor microenvironment are critical characteristics observed in patient-derived cancer xenograft models and in the clinic. By mimicking these crucial in vivo characteristics through use of 3D cultures, co-culture systems and acidic culture conditions, an in vitro cancer model/microenvironment that is more physiologically relevant may be engineered to produce results more readily applicable to the clinic.

24 December 2008 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
JGJun Guan
Jun Guan
MLMaisie Lo
Maisie Lo
PDPeter Dockery
Peter Dockery
SMSarah Mahon
Sarah Mahon
CKCristina M. Karp
Cristina M. Karp
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang

1 June 2010 in Current Oncology
Verified
Journal Article
Open access
MLM. Lo
M. Lo
VLV. Ling
V. Ling
CLC. Low
C. Low
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
PGP.W. Gout
P.W. Gout
Pancreatic cancer is an aggressive, drug-resistant disease; its first-line chemotherapeutic, gemcitabine, is only marginally effective. Intracellular depletion of glutathione, a major free-radical scavenger, has been associated with growth arrest and reduced drug resistance (chemosensitization) of cancer cells. In search of a new therapeutic approach for pancreatic cancer, we sought to determine whether specific inhibition of the plasma membrane xc− cystine transporter could lead to reduced uptake of cysteine, a key precursor of glutathione, and subsequent glutathione depletion. Sulfasalazine (approximately 0.2 mmol/L), an anti-inflammatory drug with potent xc−-inhibitory properties, markedly reduced L-[14C]-cystine uptake, glutathione levels, and growth and viability of human MIA PaCa-2 and PANC-1 pancreatic cancer cells in vitro. These effects were shown to result primarily from inhibition of cystine uptake mediated by the xc− cystine transporter and not from inhibition of nuclear factor κB activation, another property of sulfasalazine. The efficacy of gemcitabine could be markedly enhanced by combination therapy with sulfasalazine both in vitro and in immunodeficient mice carrying xenografts of the same cell lines. No major side effects were observed in vivo. The results of the present study suggest that the xc – transporter plays a major role in pancreatic cancer by sustaining or enhancing glutathione biosynthesis, and as such, represents a potential therapeutic target. Sulfasalazine, a relatively nontoxic drug approved by the U.S. Food and Drug Administration, may, in combination with gemcitabine, lead to more effective therapy of refractory pancreatic cancer.